Most Popular
-
1
10-man S. Korea lose to Indonesia to miss out on Paris Olympic football qualification
-
2
Hybe-Ador feud should have limited effect on Hybe's overall performance: analysts
-
3
Second Gimpo civil servant found dead, after apologizing for not finishing work
-
4
DP leader says he will meet Yoon without conditions
-
5
First-ever meeting of president, opposition chief set to finally happen
-
6
NewJeans' singles, Japanese debut to proceed as planned, despite Hybe-Ador feud
-
7
Experts raise concerns about Japan putting pressure on Naver over Line
-
8
Samsung mobile chief, Google device head meet in Seoul
-
9
Blinken calls on China to press N. Korea to end its 'dangerous' behavior
-
10
Ship linked to NK arms shipments to Russia is moored in China: State Dept.
Sanofi Pasteur on Tuesday launched “IDflu 15 microgram (intradermal),” the world’s first intradermal-influenza vaccine product, targeting people over 60 years old.
IDflu is a pre-filled syringe product with Vaxigrip, an influenza vaccine product in a 1.5 mm micro-injection system that is only one tenth the length of existing injection needles. It injects directly into the skin, where high density immune cells including dentritic cells and macrophages are delivered and where immune cell activity is very fast because a lot of cells and body fluids are exchanged. It is designed to reduce pain and fear caused by needles, the pharmaceutical firm said.
The product has been shown to have a 14 percent better effect with the same amount of antigens. It could benefit the elderly, who are more vulnerable to complications caused by influenza, the company said.
(baejisook@heraldcorp.com)
IDflu is a pre-filled syringe product with Vaxigrip, an influenza vaccine product in a 1.5 mm micro-injection system that is only one tenth the length of existing injection needles. It injects directly into the skin, where high density immune cells including dentritic cells and macrophages are delivered and where immune cell activity is very fast because a lot of cells and body fluids are exchanged. It is designed to reduce pain and fear caused by needles, the pharmaceutical firm said.
The product has been shown to have a 14 percent better effect with the same amount of antigens. It could benefit the elderly, who are more vulnerable to complications caused by influenza, the company said.
(baejisook@heraldcorp.com)
